SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes

SAB Biotherapeutics is a clinical-stage biotech centered on SAB-142, a disease-modifying T1D candidate targeting both stage 2 and stage 3 patients. SAB-142 may preserve beta-cell function and C-peptide with a cleaner safety profile than animal-derived immune therapies, supporting potential repeat dosing. The registrational Phase 2b SAFEGUARD study is the key value driver, while broader autoimmune programs provide secondary optionality.